Zacks Investment Research upgraded shares of OpGen Inc (NASDAQ:OPGN) from a sell rating to a hold rating in a research report released on Wednesday morning.
According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “
Separately, Rodman & Renshaw started coverage on OpGen in a report on Wednesday, June 29th. They issued a buy rating and a $2.50 target price on the stock.
OpGen (NASDAQ:OPGN) traded down 1.859% during trading on Wednesday, reaching $1.531. 25,000 shares of the company’s stock were exchanged. OpGen has a 12 month low of $1.02 and a 12 month high of $4.65. The firm’s market cap is $33.17 million. The firm’s 50-day moving average price is $1.65 and its 200-day moving average price is $1.61.
OpGen (NASDAQ:OPGN) last issued its earnings results on Tuesday, August 9th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.09. On average, equities research analysts anticipate that OpGen will post ($1.17) EPS for the current year.
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.